Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2020

Open Access 01-12-2020 | Hip-TEP | Study protocol

A protocol for a randomized controlled trial investigating the safety and cost-effectiveness of outpatient total hip arthroplasty

Authors: Bryn O. Zomar, Jacquelyn D. Marsh, Brent A. Lanting, Dianne M. Bryant

Published in: BMC Musculoskeletal Disorders | Issue 1/2020

Login to get access

Abstract

Background

A significant proportion of the overall cost of total hip arthroplasty (THA) results from the inpatient hospital stay following the procedure. Considering the substantial and increasing number of these procedures performed annually, shifting to an outpatient model of care where the patient is discharged home the same day as their surgery represents a potential for significant cost savings. The potential significant impact of an outpatient care model on constrained healthcare budgets and lack of high-quality evidence regarding its effectiveness warrants a rigorous comparative trial. The purpose of this prospective, randomized controlled trial is to evaluate outpatient care pathways for THA. Specifically, our objectives are to compare the rate of serious adverse events and estimate the cost-effectiveness of outpatient compared to standard inpatient THA.

Methods

We will include patients undergoing primary THA whom have an American Society of Anaesthetists status equal to or less than three, live within a 60-min driving distance of the institution and have an adult to accompany them home postoperatively and stay with them overnight. Consenting patients will be randomized to be discharged on the same day as surgery, as outpatients, or as inpatients according to standard of care (minimum of one night in hospital) using a modified Zelen consent model. The primary outcome measure is the incidence of serious adverse events at 30 days postoperative. Participants and their caregivers will complete secondary outcomes measures at each follow-up visit including patient-reported outcome measures and self-reported cost questionnaires.

Discussion

This protocol is the first randomized trial to use blinding to evaluate outpatient THA compared to standard overnight stay and first to prospectively perform a full economic evaluation. It is also the first adequately powered trial to prospectively assess the safety of outpatient THA. Successful completion of this study could have the potential to provide clinical evidence for the role of outpatient THA in current practice.

Trial registration

This study was retrospectively registered on ClinicalTrials.​gov (NCT03026764) on March 9th, 2016.
Literature
1.
2.
Sloan M, Premkumar A, Sheth NP. Projected volume of primary total joint arthroplasty in the U.S., 2014 to 2030. J Bone Joint Surg Am. 2018;100:1455–60.CrossRefPubMed
3.
Canadian Institute for Health Information. Hip and knee replacements in Canada, 2017–2018: Canadian joint replacement registry annual report. Ottawa: CIHI; 2019.
4.
Sutton JC III, Antoniou J, Epure LM, et al. Hospital discharge within 2 days following total hip or knee arthroplasty does not increase major-complication and readmission rates. J Bone Joint Surg Am. 2016;98:1419–28.CrossRefPubMed
5.
Aynardi M, Post Z, Ong A, et al. Outpatient surgery as a means of cost reduction in total hip arthroplasty: a case-control study. HSSJ. 2014;10:252–5.CrossRef
6.
Bertin KC. Minimally invasive outpatient total hip arthroplasty: a financial analysis. Clin Orthop Relat Res. 2005;435:154–63.CrossRef
7.
Lovald ST, Ong KL, Malkani AL, et al. Complications, mortality, and costs for outpatient and short-stay total knee arthroplasty patients in comparison to standard-stay patients. J Arthroplast. 2014;29(3):510–5.CrossRef
8.
Kolisek FR, McGrath MS, Jessup NM, et al. Comparison of outpatient versus inpatient total knee arthroplasty. Clin Orthop Relat Res. 2009;467(6):1438–42.CrossRefPubMedPubMedCentral
9.
Petis SM, Howard JL, Lanting BA, et al. In-hospital cost analysis of total hip arthroplasty: does surgical approach matter? J Arthroplast. 2016;31:53–8.CrossRef
10.
Adverse Reaction Reporting and Health Product Safety Information Guide for Health Professionals. Health Canada, Report No: 110123 ISBN: 978–1–100-18845-4.
11.
12.
Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). "Guideline for Industry - Clinical safety data management: definitions and standards for expedited reporting". FDA Center for Drug Evaluation and Research. 2007.
13.
Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–40.PubMed
14.
Soderman P, Malchau H. Is the Harris hip score system useful to study the outcome of total hip replacement? Clin Orthop Relat Res. 2001;384:189–97.CrossRef
15.
Gandhi SK, Salmon JW, Zhao SZ, et al. Psychometric evaluation of the 12-item short-form health survey (SF-12) in osteoarthritis and rheumatoid arthritis clinical trials. Clin Ther. 2001;23(7):1080–98.CrossRefPubMed
16.
Fransen M, Edmonds J. Reliability and validity of the EuroQol in patients with osteoarthritis of the knee. Rheumatology (Oxford). 1999;38(9):807–13.CrossRef
17.
Cameron JI, Franche R-L, Cheung AM, et al. Lifestyle interference and emotional distress in family caregivers of advanced Cancer patients. Cancer. 2002;94(2):521–7.CrossRefPubMed
18.
19.
20.
Bernatz JT, Tueting JL, Anderson PA. Thirty-day readmission rates in orthopedics: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0123593.CrossRefPubMedPubMedCentral
21.
Blackwelder WC. "proving the null hypothesis" in clinical trials. Control Clin Trials. 1982;3:345–53.CrossRefPubMed
22.
Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11(5):415–30.CrossRefPubMed
23.
Hoch JS, Rockx MA, Krahn AD. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope. BMC Health Serv Res. 2006;6:68.CrossRefPubMedPubMedCentral
24.
Arshi A, Leong NL, Wang C, et al. Outpatient total hip arthroplasty in the United States: a population-based comparative analysis of complication rates. J Am Acad Orthop Sur. 2019;27(2):61–7.CrossRef
25.
Basques BA, Tetreault MW, Della Valle CJ. Same-day discharge compared with inpatient hospitalization following hip and knee arthroplasty. J Bone Joint Surg Am. 2017;99:1969–77.CrossRefPubMed
26.
Courtney PM, Boniello AJ, Berger RA. Complications following outpatient total joint arthroplasty: an analysis of a national database. J Arthroplast. 2017;32:1426–30.CrossRef
27.
Lovecchio F, Alvi H, Sahota S, et al. Is outpatient arthroplasty as safe as fast-track inpatient arthroplasty? A propensity score matched analysis. J Arthroplast. 2016;31:5197–201.CrossRef
28.
Nelson SJ, Webb ML, Lukasiewicz AM, et al. Is outpatient total hip arthroplasty safe? J Arthroplast. 2017;32:1439–42.CrossRef
29.
Otero JE, Gholson JJ, Pugely AJ, et al. Length of hospitalization after joint arthroplasty: does early discharge affect complications and readmission rates? J Arthroplast. 2016;31:2714–25.CrossRef
30.
Crawford DC, Li CS, Sprague S, et al. Clinical and cost implications of inpatient versus outpatient orthopedic surgeries: a systematic review of the published literature. Orthop Rev (Pavia). 2015;7:6177.CrossRef
31.
Gromov K, Jørgensen GC, Petersen PB, Kjaersgaard-Andersen P, et al. Complications and readmissions following outpatient total hip and knee arthroplasty: a prospective 2-center study with matched controls. Acta Orthop. 2019;90(3):281–5.
32.
Hoffmann JD, Kusnezov NA, Dunn JC, et al. The shift to same-day outpatient joint arthroplasty: a systematic review. J Arthroplast. 2018;33:1265–74.CrossRef
33.
Pollock M, Somerville L, Firth A, et al. Outpatient total hip arthroplasty, total knee arthroplasty, and unicompartmental knee arthroplasty: a systematic review of the literature. JBJS Rev. 2016;4(12):1–15.CrossRef
34.
Goyal N, Chen AF, Padgett SE, et al. Otto Aufranc award: a multicenter, randomized study of outpatient versus inpatient total hip arthroplasty. Clin Orthop Relat Res. 2017;475:364–72.CrossRefPubMed
35.
Ponnusamy KE, Naseer Z, El Dafrawy MH, et al. Post-discharge care duration, charges and outcomes among Medicare patients after primary total hip and knee arthroplasty. J Bone Joint Surg Am. 2017;99(11):e55.CrossRefPubMed
36.
SooHoo NF, Farng E, Lieberman JR, et al. Factors that predict short-term complication rates after total hip arthroplasty. Clin Orthop Relat Res. 2010;468:2363–71.CrossRefPubMedPubMedCentral
37.
Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.CrossRefPubMed
38.
Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.
39.
Primeau CA, Marsh JD, Birmingham TB, et al. The importance of costing perspective: an example evaluating the cost-effectiveness of a locking versus nonlocking plate in medial opening wedge high tibial osteotomy. Can J Surg. 2019;62(1):E14–6.CrossRefPubMedPubMedCentral
Metadata
Title
A protocol for a randomized controlled trial investigating the safety and cost-effectiveness of outpatient total hip arthroplasty
Authors
Bryn O. Zomar
Jacquelyn D. Marsh
Brent A. Lanting
Dianne M. Bryant
Publication date
01-12-2020
Publisher
BioMed Central
Keywords
Hip-TEP
Hip-TEP
Published in
BMC Musculoskeletal Disorders / Issue 1/2020
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-020-03699-z

Other articles of this Issue 1/2020

BMC Musculoskeletal Disorders 1/2020 Go to the issue

Research article

Adjuvant therapy by high-speed burr may cause intraoperative bone tumor seeding: an animal study

Research article

Perceived occurrence of an adverse event affects patient-reported outcomes after total hip replacement

Study protocol

Investigating musculoskeletal health and wellbeing; a cohort study protocol

Research article

Bone impaction grafting with trabecular metal augments in large defects in young patients: unravelling a new perspective in surgical technique

Research article

Prevalence of generalized joint hypermobility in children with anxiety disorders

Research article

Development and validation of the fracture risk scale home care (FRS-HC) that predicts one-year incident fracture: an electronic record-linked longitudinal cohort study